Hughes Hubbard’s Downie and Voisin advise on Merck acquisition

Hughes Hubbard’s Downie and Voisin advise on Merck acquisition

Nadine Voisin (Left) & Sarah Downie (Right)

The pharmaceutical sector has seen a flurry of big M&A deals lately, and Hughes Hubbard & Reed partners Sarah Downie and Nadine Voisin have served on the team for another multi-billion dollar deal: Merck & Co.’s $3.85 billion purchase of Idenix Pharmaceuticals Inc.

The two companies announced the deal on June 9 after their boards approved the sale, which should close in the third quarter. Merck agreed to pay $24.50 a share for the company, triple Idenix’s closing price of $7.23 on June 6, according to the firm.

Contributing Author

author image

Amy I. Stickel

Amy I. Stickel has extensive experience covering the legal, financial and pharmaceutical industries as a writer and editor. A past managing editor of Corporate Legal Times and...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.